

REAL-WORLD EVIDENCE VALIDATES AI-BASED ENDOSCOPIC SCORING FOR ULCERATIVE COLITIS

Carmen Stefanescu

UEG Week Berlin 2025

Poster

IBD

October 7, 2025

UC-SCALE, an AI algorithm for assessing ulcerative colitis endoscopic severity, demonstrated performance in a real-world cohort from the Paris IBD Center nearly identical to its performance on Phase III clinical trial data.

KEY POINTS

- UC-SCALE was trained on Phase III Etrolizumab trial data from 471 sites and tested on a retrospective cohort of 276 unique UC patients from the Paris IBD Center.
- Agreement with expert-consensus Mayo Clinic Endoscopic Subscores was virtually identical between real-world data (quadratic-weighted kappa 0.80) and trial data (0.80).
- AUC values for discriminating MCES classes 0–3 exceeded 0.85 in all classes, with mean AUC of 0.90 in real-world data compared to 0.87 in trial data.
- Predictions for intermediate Mayo scores (1 and 2) were more accurate in the real-world cohort than in the trial dataset, with AUC differences of 0.04 and 0.08 respectively.
- This validation study is relevant to gastroenterologists and IBD specialists interested in AI-assisted endoscopic assessment tools for ulcerative colitis in routine clinical practice.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/28d07d1c-a814-11f0-9fd8-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.